This half-day CME case-based program explores the diagnosis and management of cardiac amyloidosis. After an overview of the biological basis of cardiac amyloidosis, an interactive case-based panel discussion will address the challenges of disease presentation, the role of various imaging modalities in the diagnosis, including a detailed discussion of technetium-99m pyrophosphate imaging and an overview of current and emerging treatments for transthyretin cardiac amyloidosis. The availability of new treatments has enhanced the importance of a heightened awareness, early diagnosis, and accurate typing of cardiac amyloidosis.
The American Society of Nuclear Cardiology designates this live activity for a maximum of *4.0 AMA PRA Category 1 Credits™.
For More Information: